MCID: LPC002
MIFTS: 47

Lip Cancer

Categories: Cancer diseases, Eye diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Lip Cancer

MalaCards integrated aliases for Lip Cancer:

Name: Lip Cancer 12 15
Lip Neoplasms 44 73
Malignant Neoplasm of Oral Aspect of Lip, Not Specified Whether Upper or Lower 12
Malignant Neoplasm of External Lip, Not Specified As Upper or Lower 12
Malignant Neoplasm of Labial Commissure of Lip 12
Malignant Neoplasm of Lower Lip, Buccal Aspect 12
Malignant Neoplasm of Lower Lip, Inner Aspect 12
Malignant Neoplasm of Vermilion Border of Lip 12
Malignant Neoplasm of Lower Lip, Oral Aspect 12
Malignant Neoplasm of Lip, Vermilion Border 12
Malignant Neoplasm of Other Sites of Lip 12
Malignant Neoplasm of Commissure of Lip 12
Malignant Neoplasm of Lip, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Mucosa 12
Malignant Tumor of Lower Labial Mucosa 12
Malignant Tumour of Labial Commissure 12
Malignant Tumor of Commissure of Lip 12
Malignant Neoplasm of Lip, External 12
Malignant Tumor of Labial Mucosa 12
Malignant Tumor of the Lip 12
Malignant Neoplasm of Lip 12
Malignant Tumour of Lip 12
Malignant Tumor of Lip 12
Cancer of Lip 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8564
ICD9CM 35 140 140.6 140.8
MeSH 44 D008048
NCIt 50 C7485
SNOMED-CT 68 93762003 93869001

Summaries for Lip Cancer

MalaCards based summary : Lip Cancer, also known as lip neoplasms, is related to tongue cancer and cheilitis. An important gene associated with Lip Cancer is SUMO1 (Small Ubiquitin-Like Modifier 1), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Cobalt and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and brain, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and craniofacial

Related Diseases for Lip Cancer

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to Lip Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 tongue cancer 30.7 CDKN1A TP53
2 cheilitis 29.5 MDM2 MSH2 SUMO1 TP53
3 actinic cheilitis 29.3 CDKN1A MDM2 MSH2 TP53
4 lower lip cancer 12.2
5 upper lip cancer 12.2
6 oral cancer 10.9
7 nasopharyngeal carcinoma 10.7
8 oropharynx cancer 10.5
9 oral cavity cancer 10.5
10 malignant epithelial tumor of salivary glands 10.5
11 hypopharynx cancer 10.4
12 gum cancer 10.3
13 tonsil cancer 10.3
14 salivary gland carcinoma 10.2
15 epiglottis neoplasm 10.2
16 vallecula cancer 10.2
17 soft palate cancer 10.2
18 upper gum cancer 10.2
19 uvula cancer 10.2
20 postcricoid region cancer 10.2
21 aryepiglottic fold cancer 10.2
22 tonsillar pillar cancer 10.2
23 cheek mucosa cancer 10.2
24 sublingual gland cancer 10.2
25 retromolar area cancer 10.2
26 waldeyer's ring cancer 10.2
27 tonsillar fossa cancer 10.2
28 parotid gland cancer 10.2
29 lower gum cancer 10.2
30 hard palate cancer 10.2
31 submandibular gland cancer 10.2
32 vestibule of mouth cancer 10.2
33 pyriform sinus cancer 10.2
34 cerebral primitive neuroectodermal tumor 10.1 MSH2 TP53
35 intestinal benign neoplasm 10.1 MSH2 TP53
36 ring chromosome 7 10.1 MDM2 TP53
37 zika virus infection 10.1 MDM2 TP53
38 familial colorectal cancer 10.1 MSH2 TP53
39 sclerosing liposarcoma 10.1 MDM2 TP53
40 liposarcoma 10.1 MDM2 TP53
41 uterine anomalies 10.1 MSH2 TP53
42 periosteal osteogenic sarcoma 10.1 MDM2 TP53
43 colorectal adenoma 10.1 MSH2 TP53
44 gliomatosis cerebri 10.1 MDM2 TP53
45 soft tissue sarcoma 10.1 MDM2 TP53
46 dedifferentiated liposarcoma 10.1 MDM2 TP53
47 small cell sarcoma 10.1 MDM2 TP53
48 myxosarcoma 10.1 MDM2 TP53
49 verrucous carcinoma 10.1 MDM2 TP53
50 embryonal sarcoma 10.1 MDM2 TP53

Graphical network of the top 20 diseases related to Lip Cancer:



Diseases related to Lip Cancer

Symptoms & Phenotypes for Lip Cancer

GenomeRNAi Phenotypes related to Lip Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 CDKN1A MDM2 MSH2 SUMO1 TP53

MGI Mouse Phenotypes related to Lip Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.46 CDKN1A MDM2 SUMO1 TP53
2 digestive/alimentary MP:0005381 9.35 CDKN1A MDM2 MSH2 SUMO1 TP53
3 neoplasm MP:0002006 8.92 CDKN1A MDM2 MSH2 TP53

Drugs & Therapeutics for Lip Cancer

Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Aldesleukin Approved Phase 3,Phase 2,Not Applicable 85898-30-2, 110942-02-4
5
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
6
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
7
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
8
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
10
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
11
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
12
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
13
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
18
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
19
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
20
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
21
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
22
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
23
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
24
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
25
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
26
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
27
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Porfiromycin Investigational Phase 3 801-52-5
32 Tocotrienol Investigational Phase 3 6829-55-6
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-HIV Agents Phase 3,Phase 2,Not Applicable
38 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Interleukin-2 Phase 3,Phase 2
40 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Antiviral Agents Phase 3,Phase 1,Phase 2,Not Applicable
42
s 1 (combination) Phase 3,Phase 2
43 Sympathomimetics Phase 3,Phase 2
44 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2,Not Applicable
45 Vasoconstrictor Agents Phase 3,Phase 2
46 Autonomic Agents Phase 3,Phase 2,Not Applicable
47 Epinephryl borate Phase 3,Phase 2
48 Mydriatics Phase 3,Phase 2
49 Adrenergic beta-Agonists Phase 3,Phase 2
50 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
2 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
3 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
4 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
5 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
6 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
7 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
10 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
11 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
12 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
13 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
14 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
15 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
16 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
17 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
18 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
19 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
20 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
21 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
22 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
23 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
24 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
25 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
26 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
27 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
28 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
29 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
30 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
31 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
32 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
33 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
34 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
35 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
36 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer Active, not recruiting NCT00047008 Phase 3 cisplatin
37 Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer Terminated NCT00017277 Phase 3
38 S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00006994 Phase 3 l-glutamine placebo
39 Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer Terminated NCT00360971 Phase 3 cisplatin
40 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Terminated NCT00113399 Phase 3 cisplatin;docetaxel;fluorouracil;paclitaxel
41 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
42 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
43 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
44 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Unknown status NCT00006051 Phase 2 cisplatin;fluorouracil
45 Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery Unknown status NCT00357617 Phase 1, Phase 2 celecoxib
46 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
47 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
48 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
49 Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer Unknown status NCT00566540 Phase 2 Cisplatin;Paclitaxel
50 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir

Search NIH Clinical Center for Lip Cancer

Cochrane evidence based reviews: lip neoplasms

Genetic Tests for Lip Cancer

Anatomical Context for Lip Cancer

MalaCards organs/tissues related to Lip Cancer:

41
Eye, Skin, Brain, Bone, Colon, Thyroid, Salivary Gland

Publications for Lip Cancer

Articles related to Lip Cancer:

(show top 50) (show all 111)
# Title Authors Year
1
Expression of cancer stem cell markers CD44, ALDH1 and p75NTR in actinic cheilitis and lip cancer. ( 29779037 )
2018
2
Neglected Under Lip Cancer. ( 29483993 )
2018
3
Risk of lip cancer after solid organ transplantation in the United States. ( 30074684 )
2018
4
Lip Cancer: Reconsidering the at-risk patients with pathological assessment. ( 30548899 )
2018
5
AHNS Series - Do you know your guidelines? Lip cancer. ( 28580768 )
2017
6
Clinicopathological study of lip cancer: a retrospective hospital-based study in Taiwan. ( 28913905 )
2017
7
Changes in the Incidence of Skin and Lip Cancer Between 1978 and 2007. ( 28190452 )
2017
8
Hydrochlorothiazide use is strongly associated with risk of lip cancer. ( 28480532 )
2017
9
Intraoral stents in preventing adverse radiotherapeutic effects in lip cancer patients. ( 28883766 )
2017
10
Stage is a prognostic factor for surgically treated patients with early-stage lip cancer for whom a 'wait and see' policy in terms of neck status has been implemented. ( 28807064 )
2017
11
Two-Piece Extraoral Prosthetic Rehabilitation to a Perineural Invasion Lip Cancer. ( 27517479 )
2016
12
Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. ( 27628318 )
2016
13
Lip cancer: A 16-year retrospective epidemiological study in Eastern part of Turkey. ( 27812062 )
2016
14
Correlation between cell cycle proteins and hMSH2 in actinic cheilitis and lip cancer. ( 26842232 )
2016
15
Lip Cancer: A Clinicopathological Study and Treatment Outcomes in a 25-Year Experience. ( 26917204 )
2016
16
Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. ( 27841120 )
2016
17
High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. ( 26830865 )
2016
18
Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations. ( 26084614 )
2015
19
Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. ( 25753473 )
2015
20
The pattern of lip cancer occurrence over the 1990-2011 period in public hospitals in Madrid, Spain. ( 26256568 )
2015
21
Oral and lip cancer in solid organ transplant patients--a cohort study from a Swedish Transplant Centre. ( 25497104 )
2015
22
Long-term outcome and subjective quality of life after surgical treatment of lower lip cancer. ( 25261402 )
2014
23
Early diagnosis of lip cancer preceded by a persistent actinic lesion in a kidney transplant patient: a case report. ( 24983181 )
2014
24
Quantification of the Surgical Margin Shrinkage in Lip Cancer: Determining the Relation Between the Surgical and Histopathologic Margins. ( 25329844 )
2014
25
Facial cutaneous metastases of advanced rectal malignancy masquerading as lip cancer. ( 25370567 )
2014
26
Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. ( 25241153 )
2014
27
Technique for histological control of surgical margins in lip cancer. ( 24611955 )
2014
28
Pulsed dose rate brachytherapy of lip cancer. ( 24143149 )
2013
29
Antihypertensive drugs and lip cancer in non-Hispanic whites. ( 22869299 )
2012
30
High dose-rate versus low dose-rate brachytherapy for lip cancer. ( 22099044 )
2012
31
Lip cancer: a 10-year retrospective epidemiological study. ( 22493399 )
2012
32
Lip cancer: retrospective analysis of 181 cases. ( 22136191 )
2012
33
Wave technique for treatment of lower lip cancer. ( 22440315 )
2012
34
Sun protection for all: but especially for those receiving certain hypertensive medications: comment on "Antihypertensive drugs and lip cancer in non-Hispanic whites". ( 22869333 )
2012
35
High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on 12 consecutive patients and review of the literature. ( 23052164 )
2012
36
Surgical management of lip cancer. ( 21808457 )
2011
37
Lip cancer in renal transplant patients. ( 21112239 )
2011
38
Long term results of PDR brachytherapy for lip cancer. ( 27895671 )
2011
39
Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study. ( 20383781 )
2010
40
Lip cancer: incidence, trends, histology and survival: 1970-2006. ( 20163415 )
2010
41
Lip cancer: a 5-year review in a tertiary referral centre. ( 20129833 )
2010
42
HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology. ( 28031737 )
2010
43
Surgical treatment of lip cancer: our experience with 106 cases. ( 19304043 )
2009
44
Lip cancer in Western Australia, 1982-2006: a 25-year retrospective epidemiological study. ( 19473154 )
2009
45
Is elective neck dissection in T1-2, N0 patients with lower lip cancer necessary? ( 19325341 )
2009
46
Immunosuppression and other risk factors for lip cancer after kidney transplantation. ( 19190169 )
2009
47
Survival after lip cancer diagnosis. ( 19165039 )
2009
48
Sentinel lymph node biopsy (SLNB) in management of N0 stage T1-T2 lip cancer as a "same day" procedure. ( 17936674 )
2008
49
Comparison of time trends in lip cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII. ( 18573854 )
2008
50
Continuous intraarterial infusion chemotherapy for early lip cancer. ( 17207655 )
2007

Variations for Lip Cancer

Expression for Lip Cancer

Search GEO for disease gene expression data for Lip Cancer.

Pathways for Lip Cancer

Pathways related to Lip Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 CDKN1A MDM2 MSH2 SUMO1 TP53
2
Show member pathways
13.19 CDKN1A MDM2 SUMO1 TP53
3
Show member pathways
12.77 CDKN1A MDM2 MSH2 TP53
4
Show member pathways
12.66 CDKN1A MDM2 MSH2 TP53
5 12.62 CDKN1A MDM2 MSH2 TP53
6
Show member pathways
12.61 CDKN1A MDM2 TP53
7
Show member pathways
12.57 CDKN1A MDM2 TP53
8
Show member pathways
12.54 CDKN1A MDM2 TP53
9
Show member pathways
12.42 CDKN1A MSH2 TP53
10
Show member pathways
12.41 MDM2 SUMO1 TP53
11
Show member pathways
12.4 CDKN1A MDM2 TP53
12
Show member pathways
12.38 CDKN1A MDM2 SUMO1 TP53
13 12.35 CDKN1A MDM2 TP53
14
Show member pathways
12.32 CDKN1A MDM2 TP53
15
Show member pathways
12.26 CDKN1A MDM2 MSH2 SUMO1 TP53
16 12.25 CDKN1A MDM2 MSH2 TP53
17
Show member pathways
12.24 CDKN1A MDM2 TP53
18
Show member pathways
12.22 CDKN1A MDM2 TP53
19 12.21 CDKN1A MDM2 TP53
20 12.15 CDKN1A MDM2 TP53
21 12.14 CDKN1A MDM2 TP53
22 12.14 CDKN1A MDM2 TP53
23 12.1 CDKN1A MDM2 TP53
24
Show member pathways
12.09 CDKN1A MDM2 TP53
25
Show member pathways
12.04 CDKN1A MDM2 TP53
26 12.03 CDKN1A MSH2 TP53
27 12.01 CDKN1A MDM2 TP53
28 11.99 MDM2 MSH2 TP53
29 11.98 CDKN1A MDM2 TP53
30 11.9 CDKN1A SUMO1 TP53
31 11.83 CDKN1A MDM2 TP53
32 11.81 CDKN1A MDM2 TP53
33 11.79 CDKN1A MDM2 SUMO1 TP53
34 11.77 CDKN1A MDM2 TP53
35 11.74 CDKN1A MDM2 MSH2 TP53
36 11.69 CDKN1A MDM2 SUMO1
37 11.67 CDKN1A MDM2 TP53
38
Show member pathways
11.65 MSH2 TP53
39
Show member pathways
11.65 CDKN1A MDM2 TP53
40 11.61 CDKN1A MDM2 TP53
41
Show member pathways
11.59 MDM2 TP53
42 11.53 CDKN1A MDM2 TP53
43 11.49 MDM2 TP53
44 11.47 CDKN1A MDM2
45 11.45 MDM2 TP53
46 11.45 MDM2 TP53
47 11.42 CDKN1A TP53
48 11.42 CDKN1A TP53
49 11.41 CDKN1A TP53
50 11.4 CDKN1A MDM2 SUMO1 TP53

GO Terms for Lip Cancer

Cellular components related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.55 CDKN1A MDM2 MSH2 SUMO1 TP53
2 nucleolus GO:0005730 9.26 CDKN1A MDM2 SUMO1 TP53
3 nuclear body GO:0016604 8.92 CDKN1A MDM2 SUMO1 TP53

Biological processes related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.77 CDKN1A MSH2 TP53
2 viral process GO:0016032 9.73 MDM2 SUMO1 TP53
3 regulation of signal transduction by p53 class mediator GO:1901796 9.6 MDM2 TP53
4 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.58 MDM2 SUMO1
5 Ras protein signal transduction GO:0007265 9.58 CDKN1A TP53
6 cellular response to heat GO:0034605 9.57 CDKN1A SUMO1
7 protein sumoylation GO:0016925 9.55 MDM2 SUMO1
8 cellular response to ionizing radiation GO:0071479 9.54 CDKN1A TP53
9 intrinsic apoptotic signaling pathway GO:0097193 9.52 CDKN1A TP53
10 response to antibiotic GO:0046677 9.51 MDM2 TP53
11 positive regulation of reactive oxygen species metabolic process GO:2000379 9.49 CDKN1A TP53
12 cellular response to gamma radiation GO:0071480 9.48 MDM2 TP53
13 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.46 MSH2 TP53
14 response to X-ray GO:0010165 9.43 CDKN1A MSH2
15 cell cycle arrest GO:0007050 9.43 CDKN1A MSH2 TP53
16 positive regulation of protein export from nucleus GO:0046827 9.4 MDM2 TP53
17 determination of adult lifespan GO:0008340 9.37 MSH2 TP53
18 replicative senescence GO:0090399 9.32 CDKN1A TP53
19 signal transduction by p53 class mediator GO:0072331 9.16 CDKN1A TP53
20 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.13 CDKN1A MDM2 TP53
21 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.54 CDKN1A MSH2 TP53
2 p53 binding GO:0002039 9.32 MDM2 TP53
3 disordered domain specific binding GO:0097718 9.26 MDM2 TP53
4 enzyme binding GO:0019899 9.26 MDM2 MSH2 SUMO1 TP53
5 SUMO transferase activity GO:0019789 9.16 MDM2 SUMO1
6 ubiquitin protein ligase binding GO:0031625 8.92 CDKN1A MDM2 SUMO1 TP53

Sources for Lip Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....